Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations.

Autor:	Cochrane AB; Inova Fairfax Hospital, Falls Church, Virginia. Electronic address: adam.cochrane@inova.org., Lyster H; Royal Brompton & Harefield Hospital NHS Foundation Trust, London, United Kingdom., Lindenfeld J; Vanderbilt University School of Medicine, Nashville, Tennessee., Doligalski C; University of North Carolina Health System, Chapel Hill, North Carolina., Baran D; Sentara Norfolk General Hospital, Eastern Virginia Medical School, Norfolk, Virginia., Yost C; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Shullo M; West Virginia University Health System, Morgantown, West Virginia., Schweiger M; University Children's Hospital Zurich, Zurich, Switzerland., Weill D; Weill Consulting Group, New Orleans, Louisiana., Stuckey L; University of Michigan Health System, Ann Arbor, Michigan., Ivulich S; The Alfred Hospital, Melbourne, Australia., Scheel J; St Louis Children's Hospital, Washington University of St Louis School of Medicine, St Louis, Missouri., Peters L; Washington Hospital Center, Washington, District of Columbia., Colvin M; University of Michigan School of Medicine, Ann Arbor, Michigan., Dawson K; University of Kentucky Health System, Lexington, Kentucky., Girgis R; Spectrum Health System, Grand Rapids, Michigan., Weeks P; Memorial Hermann Texas Medical Center, Houston, Texas., Tse T; Queensland Health, Chermside, Australia., Russell S; Duke University Health System, Durham, North Carolina., Flattery M; Virginia Commonwealth University Health System, Richmond, Virginia., Jennings D; Columbia University Health System, New York, New York., Kittleson M; Cedars Sinai Health System, Los Angeles, California., Miller T; Duke University Health System, Durham, North Carolina., Khuu T; University of California Los Angeles, Los Angeles, California., Claridge T; Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Uber P; Tampa General Hospital, Tampa, Florida., Ford K; Great Ormond Street Hospital for Children, London, United Kingdom., Ensor CR; AdventHealth, Orlando, Florida., Simpson K; Washington University of St Louis, St Louis, Missouri., Dipchand A; The Hospital for Sick Children, Toronto, Canada., Page RL 2nd; University of Colorado School of Pharmacy, Denver, Colorado.
Jazyk:	angličtina
Zdroj:	The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation [J Heart Lung Transplant] 2020 Oct; Vol. 39 (10), pp. 1050-1069. Date of Electronic Publication: 2020 Jul 10.
DOI:	10.1016/j.healun.2020.06.024
Abstrakt:	In 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation. (Copyright © 2020 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu